This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
between 18 and 55
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The main purpose of this study is to determine if oxycodone and naltrexone combination capsules (ALO-02) have the potential to be abused.

Provided treatments

  • Drug: Placebo
  • Drug: intact ALO-02 60 mg/7.2 mg
  • Drug: crushed ALO-02 60 mg/7.2 mg
  • Drug: crushed oxycodone IR 60 mg
  • Drug: crushed ALO-02 40 mg/4.8 mg
  • Drug: crushed oxycodone IR 40 mg

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01746901. The sponsor of the trial is Pfizer and it is looking for 32 volunteers for the current phase.
Official trial title:
A Randomized, Double-blind, Double-dummy, Placebo Controlled, Single-Dose, 6-Way Crossover Study to Determine the Relative Abuse Potential of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules) Compared to Oxycodone Immediate Release and Placebo When Administered Orally to Non-Dependent, Recreational Opioid Users